Gender-specific association of the plasminogen activator inhibitor-1 4g/5G polymorphism with central arterial blood pressure

American Journal of Hypertension

Volumn 24, Issue 7, 2011, Pages 802-808

  Björck, Hanna M ^a   Eriksson, Per ^b   Alehagen, Urban ^a   De Basso, Rachel ^a   Ljungberg, Liza U ^a   Persson, Karin ^a   Dahlström, Ulf ^a   Länne, Toste ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

aorta; arterial stiffness; blood pressure; genetics; hypertension; pressure pulse wave

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1;

AGED; ARTERIAL PRESSURE; ARTICLE; BRACHIAL ARTERY; CENTRAL ARTERIAL PRESSURE; COHORT ANALYSIS; CORRELATION ANALYSIS; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GERIATRIC PATIENT; HETEROZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; RADIAL ARTERY; RISK FACTOR; SEX DIFFERENCE; WAVEFORM;

AGED; AGED, 80 AND OVER; BLOOD PRESSURE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERTENSION; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; RISK FACTORS; SEX CHARACTERISTICS; SWEDEN;

EID: 79959365714     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2011.63     Document Type: Article

References (40)

1. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996; 383:441-443. (Pubitemid 26330833)
2. Kouri FM, Queisser MA, Königshoff M, Chrobak I, Preissner KT, Seeger W, Eickelberg O. Plasminogen activator inhibitor type 1 inhibits smooth muscle cell proliferation in pulmonary arterial hypertension. Int J Biochem Cell Biol 2008; 40:1872-1882.
3. Hamsten A, de Faire U, Walldius G, Dahlén G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2:3-9. (Pubitemid 17083665)
4. Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313:1557-1563. (Pubitemid 16177394)
5. Sundell IB, Nilsson TK, Rånby M, Hallmans G, Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a crosssectional study in Norsjö, Sweden. J Clin Epidemiol 1989; 42:719-723. (Pubitemid 19213116)
6. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, Mittleman MA, Muller JE, D'Agostino RB, Wilson PW, Levy D. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101:264-269. (Pubitemid 30054153)
7. Jeng JR. Association of PAI-1 gene promoter 4g/5g polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension. Am J Hypertens 2003; 16:290-296.
8. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268:10739-10745. (Pubitemid 23162248)
9. Eriksson P, Kallin B, van 't Hooft FM, Båvenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92:1851-1855.
10. Martínez-Calatrava MJ, González-Sánchez JL, Zabena C, Martínez-Larrad MT, Luque-Otero M, Serrano-Ríos M. Is the plasminogen activator inhibitor-1 gene a candidate gene predisposing to hypertension? Results from a population-based study in Spain. J Hypertens 2007; 25:773-777. (Pubitemid 46398871)
11. Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Büller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation 2001; 104:3063-3068. (Pubitemid 34014058)
12. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, Umans JG, Howard BV. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50:197-203. (Pubitemid 46986041)
13. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc'h PM, London GM. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39:735-738. (Pubitemid 34252866)
14. Jankowski P, Kawecka-Jaszcz K, Bryniarski L, Czarnecka D, Brzozowska-Kiszka M, Posnik-Urbanska A, Kopec G, Dragan J, Klecha A, Dudek D. Fractional diastolic and systolic pressure in the ascending aorta are related to the extent of coronary artery disease. Am J Hypertens 2004; 17:641-646. (Pubitemid 39091543)
15. Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, Vaughan DE, van Gilst WH, Moore JH. Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits. J Thromb Haemost 2007; 5:313-320. (Pubitemid 46139456)
16. Schoenhard JA, Asselbergs FW, Poku KA, Stocki SA, Gordon S, Vaughan DE, Brown NJ, Moore JH, Williams SM. Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population. Hum Genet 2008; 124:479-488.
17. Alehagen U, Ericsson A, Dahlström U. Are there any significant differences between females and males in the management of heart failure? Gender aspects of an elderly population with symptoms associated with heart failure. J Card Fail 2009; 15:501-507.
18. Björck HM, Länne T, Alehagen U, Persson K, Rundkvist L, Hamsten A, Dahlström U, Eriksson P. Association of genetic variation on chromosome 9p21.3 and arterial stiffness. J Intern Med 2009; 265:373-381.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
20. Kool MJ, van Merode T, Reneman RS, Hoeks AP, Struyker Boudier HA, Van Bortel LM. Evaluation of reproducibility of a vessel wall movement detector system for assessment of large artery properties. Cardiovasc Res 1994; 28:610-614. (Pubitemid 24199173)
21. Hoeks AP, Willekes C, Boutouyrie P, Brands PJ, Willigers JM, Reneman RS. Automated detection of local artery wall thickness based on M-line signal processing. Ultrasound Med Biol 1997; 23:1017-1023. (Pubitemid 27387840)
22. van der Heijden-Spek JJ, Staessen JA, Fagard RH, Hoeks AP, Boudier HA, van Bortel LM. Effect of age on brachial artery wall properties differs from the aorta and is gender dependent: a population study. Hypertension 2000; 35: 637-642. (Pubitemid 30108161)
23. Länne T, Stale H, Bengtsson H, Gustafsson D, Bergqvist D, Sonesson B, Lecerof H, Dahl P. Noninvasive measurement of diameter changes in the distal abdominal aorta in man. Ultrasound Med Biol 1992; 18:451-457.
24. Kawasaki T, Sasayama S, Yagi S, Asakawa T, Hirai T. Non-invasive assessment of the age related changes in stiffness of major branches of the human arteries. Cardiovasc Res 1987; 21:678-687. (Pubitemid 17137746)
25. Margaglione M, Grandone E, Vecchione G, Cappucci G, Giuliani N, Colaizzo D, Celentano E, Panico S, Di Minno G. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes. Arterioscler Thromb Vasc Biol 1997; 17:2082-2087. (Pubitemid 28057111)
26. Festa A, D'Agostino R Jr, Rich SS, Jenny NS, Tracy RP, Haffner SM. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Circulation 2003; 107:2422-2427. (Pubitemid 36605223)
27. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113:1213-1225.
28. Hope SA, Tay DB, Meredith IT, Cameron JD. Use of arterial transfer functions for the derivation of aortic waveform characteristics. J Hypertens 2003; 21:1299-1305.
29. Davies JI, Band MM, Pringle S, Ogston S, Struthers AD. Peripheral blood pressure measurement is as good as applanation tonometry at predicting ascending aortic blood pressure. J Hypertens 2003; 21:571-576. (Pubitemid 36418969)
30. Krishnamurti C, Tang DB, Barr CF, Alving BM. Plasminogen activator and plasminogen activator inhibitor activities in a reference population. Am J Clin Pathol 1988; 89:747-752.
31. van Harmelen V, Wahrenberg H, Eriksson P, Arner P. Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue. Thromb Haemost 2000; 83:304-308. (Pubitemid 30093236)
32. Asselbergs FW, Williams SM, Hebert PR, Coffey CS, Hillege HL, Navis G, Vaughan DE, van Gilst WH, Moore JH. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thromb Haemost 2006; 96:471-477. (Pubitemid 44560681)
33. Sartori MT, Vettor R, De Pergola G, De Mitrio V, Saggiorato G, Della Mea P, Patrassi GM, Lombardi AM, Fabris R, Girolami A. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance. Thromb Haemost 2001; 86:1161-1169. (Pubitemid 33064562)
34. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44:37-42.
35. Lin HF, Liu CK, Liao YC, Lin RT, Chen CS, Juo SH. The risk of the metabolic syndrome on carotid thickness and stiffness: sex and age specific effects. Atherosclerosis 2010; 210:155-159.
36. Eriksson P, Reynisdottir S, Lönnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998; 41:65-71. (Pubitemid 28105743)
37. Fogari R, Zoppi A, Preti P, Fogari E, Malamani G, Mugellini A. Differential effects of ACE-inhibition and angiotensin II antagonism on fibrinolysis and insulin sensitivity in hypertensive postmenopausal women. Am J Hypertens 2001; 14:921-926. (Pubitemid 32862593)
38. Sakata K, Shirotani M, Yoshida H, Urano T, Takada Y, Takada A. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. Am Heart J 1999; 137:1094-1099. (Pubitemid 30040734)
39. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32:965-971. (Pubitemid 29001421)
40. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO 3rd. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997; 336:683-690. (Pubitemid 27102682)